Plain-English translation of NCT06207656 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a combination of three drugs—cetuximab, encorafenib, and binimetinib—can help shrink advanced colorectal cancer before surgery in patients whose tumors have a specific genetic change called BRAF V600E. Previous research showed that this medication combination worked better than standard treatment, with more patients responding and living longer. Researchers want to see if using this treatment before surgery can help even more patients.
Patients with this type of colorectal cancer have very poor outcomes with standard treatments and few good options. This trial exists to find a better way to treat these patients by using this medication combination earlier in their care—before surgery—to give them the best chance of success.
You likely qualify if…
You likely don't qualify if…
You would take three oral medications daily (two pills in the morning and throughout the day, one by mouth) and receive one intravenous infusion of the third medication every two weeks, all in 28-day cycles. You will have regular clinic visits, blood tests, and imaging scans to check how well the treatment is working and monitor for side effects. The goal is to shrink your cancer enough to make surgery possible, after which you may receive additional standard care as recommended by your doctor.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Spain